A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety, and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment
Phase of Trial: Phase III
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Albusomatropin (Primary)
- Indications Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2016 Status changed from active, no longer recruiting to discontinued as per the Business decision.
- 02 Mar 2016 Planned End Date changed from 1 Feb 2018 to 1 Apr 2016 ClinicalTrials.gov record.